Total Funding
82
48
Total FundingSeries A raised
Growth Score
-5 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
14164
Trogenix is a biotech company that develops precision cancer treatments that selectively target diseased cell states and behaviour.
- Ken Macnamara: CEOPast Role: Asklepios BioPharmaceutical, CPO
About the Company
Trogenix develops precision genetic medicines using its Odysseus platform, which harnesses Synthetic Super-Enhancers (SSEs) to distinguish cancer cell states from healthy ones and drive selective payload delivery. Its methodology combines controlled cell killing, immune modulation, and long-term protection against recurrence. The company pursues
therapeutic programmes in aggressive solid tumours, notably glioblastoma, and explores expansion into colorectal liver metastases, hepatocellular carcinoma, and lung cancer. Trogenix also partners with manufacturing and development specialists (e.g. Viralgen) to accelerate production of its gene therapy assets.
